In early studies, the efficacy of anti-TNF-α and IL-1 receptor-antagonist therapies in human sepsis were disappointing, partly because TNF-α and IL-1β were released early in the development of sepsis, thereby limiting the effect of such therapies. This evidence concerns the gene IL1B and Sepsis.